CS-8958 - A Phase I, Double-Blind, Placebo Controlled, Ascending Single Inhaled Dose, Safety, Tolerability and Pharmacokinetic Study in Elderly Subjects

Trial Profile

CS-8958 - A Phase I, Double-Blind, Placebo Controlled, Ascending Single Inhaled Dose, Safety, Tolerability and Pharmacokinetic Study in Elderly Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Laninamivir (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors Biota Holdings
  • Most Recent Events

    • 16 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jan 2009 Planned number of patients changed from 24 to 38 as reported by ClinicalTrials.gov.
    • 12 Jan 2009 Planned end date changed from 1 Sep 2008 to 1 Jun 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top